AGTR2 and prostate carcinoma: Selective activation of the AT2 receptor has been suggested as therapy for human prostate cancer based on rat studies where the AT2 agonist compound 21 reduced both androgen receptor expression and the proliferative activity of prostate cancer cells in a rat model of disease (30).